Citius Oncology (CTOR) Goodwill & Intangibles (2024 - 2026)
Citius Oncology (CTOR) posted quarterly Goodwill & Intangibles of $73.4 million for Q1 2026, up 0.79% quarter-over-quarter from $72.8 million in Q4 2025.
Citius Oncology (CTOR) Goodwill & Intangibles (2024 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Goodwill & Intangibles for 3 consecutive years, with $73.4 million the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Citius Oncology | 79.23 Mn | 79.23 Mn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.40 Mn |
| Dec 31, 2025 | 72.83 Mn |
| Dec 31, 2024 | 72.83 Mn |